24th week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130149317 | MALARIA VACCINE - The present invention relates to a malaria vaccine comprising: | 2013-06-13 |
20130149318 | PAINTING THE PIA, ARACHNOID, AND SPINAL CORD PARENCHYMA - A PEG based hydrogel and a procedure for its topical application to the surface of the pia mater of the spinal cord that can be used for intrathecal delivery of diverse drug and biomolecular therapies for the treatment of traumatic central nervous system injuries and disorders including spinal cord injury (SCI), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are provided. This “painting of the pia” with biofunctionalized hydrogel material may be used as a prelude strategy in the therapeutic management of these CNS disorders. The strategy may be designed to create a microenvironment within the damaged regions of the spinal cord that is more conducive to the successful application of subsequent regeneration based treatments such as cell replacement therapies or endogenous regeneration and plasticity stimulation via application of growth factors or gene therapy. Compositions and methods for topical application of the PEG based hydrogel to the arachnoid mater, the intrathecal portions of the spinal nerves, and application directly to the spinal cord parenchyma are also provided. | 2013-06-13 |
20130149319 | ANTICANCER COMPOSITION - Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A). | 2013-06-13 |
20130149320 | Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer - The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for treating cancer. | 2013-06-13 |
20130149321 | CANDIDATES AGAINST INFECTION - The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model. | 2013-06-13 |
20130149322 | PROCESS FOR EXTRACTING MATERIALS FROM BIOLOGICAL MATERIAL - The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid. | 2013-06-13 |
20130149323 | MUTATED LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS - A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier. | 2013-06-13 |
20130149324 | THERAPEUTIC TB VACCINE - Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis. | 2013-06-13 |
20130149325 | PORPHYROMONAS GINGIVALIS POLYPEPTIDES AND NUCLEOTIDES - The present invention relates to isolated | 2013-06-13 |
20130149326 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 2013-06-13 |
20130149327 | YERSINIA PESTIS ANTIGENS, VACCINE COMPOSITIONS, AND RELATED METHODS - The present invention provides antigens and vaccines useful in prevention of infection by | 2013-06-13 |
20130149328 | PLANT-DERIVED CHOLERA AND MALARIA VACCINE - Described herein are methods for simultaneously immunizing a subject against Cholera and Malarial infection. Specifically exemplified herein are methods that involve administering compositions comprising a CTB-AMA1 or CTB-MSP1 derived from plants having plastids transformed to express such conjugates. | 2013-06-13 |
20130149329 | BROADLY PROTECTIVE SHIGELLA VACCINE BASED ON TYPE III SECRETION APPARATUS PROTEINS - Broad-based, cross-protective, O-serotype independent vaccines against | 2013-06-13 |
20130149330 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF BLOCKING BACILLUS ANTHRACIS - The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of | 2013-06-13 |
20130149331 | RHAMNOSE AND FORSSMAN CONJUGATED IMMUNOGENIC AGENTS - The present invention provides an immunogenic composition comprising a T-cell antigen in association with a rhamnose monosaccharide and/or Forssman disaccharide, and corresponding methods for inducing immune response. The T-cell antigen may be for example, a tumor vaccine, such as a tumor cell or one or more tumor antigens. The invention takes advantage of the naturally high titers of anti-Rhamnose and/or anti-Forssman disaccharide in humans to target vaccine compositions to antigen presenting cells. | 2013-06-13 |
20130149332 | Methods for Enhanced Somatostatin Immunogenicity in the Treatment of Obesity - Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1. | 2013-06-13 |
20130149333 | PHARMACEUTICAL PRODUCTS FROM FUNGAL STRAINS - Disclosed herein are compositions comprising an isolated cellulose degrading fungus and pharmaceutical substances produced by the fungus. | 2013-06-13 |
20130149334 | CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 2013-06-13 |
20130149335 | PROTEIN FORMULATIONS - The invention relates to the discovery that the addition of aromatic carboxylate ions inhibit protein instability caused by aromatic preservatives. Thus, the invention relates to compositions, (preferably aqueous compositions, comprising a protein, an aromatic preservative and aromatic carboxylate ions. The proteins remain stable and suitable for storage at ambient temperatures or lower, even in aqueous form. Preferably, the aqueous composition comprises a protein, a phenolic preservative and benzoate ions, wherein the pH of the composition is at least 1 unit greater than the pK | 2013-06-13 |
20130149336 | Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries - The invention is directed to methods of screening immunogenic viral like particles and related immunogenic compositions and diagnostic techniques. In one embodiment, the invention provides methods of screening immunogenic viral like particles containing peptides corresponding to epitope regions of a wide variety of pathogens, including viruses, bacteria, parasites, and microbes. Non-infectious antigens and allergens of interest can also be screened as described herein. Immunization, therapeutic and diagnostic applications are also described for the compositions and methods according to the invention. | 2013-06-13 |
20130149337 | METHOD OF CONTROLLING ADMINISTRATION OF CANCER ANTIGEN - The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases. | 2013-06-13 |
20130149338 | COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS - Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration. | 2013-06-13 |
20130149339 | COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS - It was found that bacteria belonging to the genus | 2013-06-13 |
20130149340 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 2013-06-13 |
20130149341 | METHODS OF IMPROVING SKIN QUALITY - Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs. | 2013-06-13 |
20130149342 | COMPOSITION COMPRISING PROBIOTIC BACTERIA FOR USE IN THE TREATMENT OF IMMUNE DISORDERS - The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis. | 2013-06-13 |
20130149343 | Hemostatic Bioabsorbable Device with Polyethylene Glycol Binder - A hemostatic pad comprising a bioabsorbable scaffolding material; a lyophilized thrombin powder, a lyophilized fibrinogen powder, and a meltable binder powder, with all powders disposed on the bioabsorbable scaffolding material. A meltable binder such as PEG bonds the lyophilized thrombin powder and the lyophilized fibrinogen powder to the bioabsorbable scaffolding material for improved friability, wettability and performance in a use, such as for hemostatic treatment or sealing at a wound site. | 2013-06-13 |
20130149345 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE - The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20% (w/w) leucine, about 75% (w/w) calcium lactate, and about 5% (w/w) sodium chloride, or about 37.5% (w/w) leucine, about 58.6% (w/w) calcium lactate, and about 3.9% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders. | 2013-06-13 |
20130149346 | DABIGATRAN ETEXILATE-CONTAINING PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition containing dabigatran etexilate or a pharmaceutically acceptable salt thereof as active ingredient. | 2013-06-13 |
20130149347 | ISOLATED RENAL CELLS AND USES THEREOF - The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations. | 2013-06-13 |
20130149348 | HYDROXYAPATITE TISSUE FILLER AND ITS PREPARATION AND USE - The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than | 2013-06-13 |
20130149349 | USE OF COMPOUNDS WITH THROMBOPOIETIC ACTIVITY TO PROMOTE BONE GROWTH AND HEALING - TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals. | 2013-06-13 |
20130149350 | Pharmacokinetics of S-Adenosylmethionine Formulations - Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning. | 2013-06-13 |
20130149351 | POLYMER SCAFFOLDS AND THEIR USE IN THE TREATMENT OF VISION LOSS - The present invention provides for scaffolds for growing RPE cells, comprising two or more biodegradable polymers. The present invention also provides for methods for creating a scaffold for growing RPE cells. Additionally, the present invention provides for RGD peptide linked polymer scaffolds for supporting the growth of RPE cells. The present invention provides methods of culturing RPE cells using the scaffolds produced herein. The present invention also provides methods of treating vision loss through the administration of RPE cell attached RGD peptide linked polymer scaffolds produced herein. The present invention further provides kits for treating vision loss. | 2013-06-13 |
20130149352 | APPARATUS AND METHOD FOR THE TREATMENT OF ABNORMAL UTERINE BLEEDING - Method and apparatus are disclosed for applying a therapeutic amount of a vasoconstrictor within the vaginal canal to control abnormal uterine bleeding. The abnormal bleeding can be due to excessive menstrual blood flow, bleeding from a surgical procedure, postpartum bleeding or any other acute or chronic condition. The vasoconstrictor includes topical agents such as an alpha-adrenergic agonist, for example oxymetazoline. The vasoconstrictor can be applied within the vaginal canal using any of many delivery apparatus. The vasoconstrictor can be included on a carrier member that is positioned in the vaginal canal and remains in place for a period of time, such as a tampon. In some embodiments, the carrier member can be a polymer ring or other shape that is inserted in the upper portion of the vaginal canal, such as the formix area. | 2013-06-13 |
20130149353 | Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit - A solid dosage form designed to facilitate rapid and reliable oral, esophageal and GI transit has a surface area of the contact patch, i.e., the area of contact between the dosage form and the bodily surface reduced. The dosage form can be an asymmetric oral dosage unit containing a bioactive, the dosage unit being asymmetric with respect to a rotational axis perpendicular to a longitudinal axis of the dosage form, the rotational axis being located substantially at a mid point along the longitudinal axis. The dosage unit may have an outer surface ridged or dimpled or have at least one annular ring so as to reduce the contact patch of the dosage unit with a flat surface compared to non-ridged dosage unit of the same size and shape. The oral dosage unit can also have a spherical shape with or without ridges and/or dimples. Dies for forming these oral dosage units have, in a closed state, a cavity having a shape corresponding to the oral dosage unit. | 2013-06-13 |
20130149354 | COATED ELASTOMERIC ARTICLE AND METHOD FOR MAKING A COATED ELASTOMERIC ARTICLE - An elastomeric article, such as a glove or a condom, is coated with a compound containing silicone, collagen and allantoin. | 2013-06-13 |
20130149355 | HYDROXYAPATITE-TARGETING POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS - Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided. | 2013-06-13 |
20130149356 | Muscle-based grafts/implants - The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic agent to attract a desired cell. | 2013-06-13 |
20130149357 | Porous Degradable Polyelectrolyte Microspheres as Vaccine Vector - The present invention discloses a composition comprising a polyelectrolyte complex and a polyol, characterised in that said polyol is in amorphous form. Optionally, the composition further comprises one or more drugs, wherein each drug has a molecular weight of at least 1000 Dalton. Said compositions are obtainable by spray-drying. The compositions may be prepared in particle form and as a suspension of particles. Pharmaceutical compositions are also provided for use in extracellular drug delivery. Pharmaceutical compositions are also provided that exhibit a controlled dual drug release. | 2013-06-13 |
20130149358 | Wash Resistant Compositions Containing Aminosilicone - Compositions and methods are disclosed for imparting a long-wearing color to keratin fibers, including hair. More specifically, the invention relates to cosmetic compositions and methods for improving retention of particulate materials, such as pigments, on hair to artificially color the hair and/or to impart other aesthetic benefits to the hair. The compositions comprise at least one aminosilicone polymer having at least one diamino functional group, and a functional group equivalent weight (FGEW) from about 1,000 to about 2,000 g/mol and a non-spherical particulate material, preferably a pigment or a lake. | 2013-06-13 |
20130149359 | Effervescent Mouthwash - The present invention comprises an effervescent composition containing an antiseptically effective amount of phytochemicals, flavonoids, and/or antimicrobial agents comprising an effective amount of polyphenols derived from a plant selected from the group consisting of White tea, Green tea, Oolong tea, Black tea, | 2013-06-13 |
20130149360 | ADMINISTRATION OF COUMARIN, BUTYLATED HYDROXYANISOLE AND ETHOXYQUINE FOR THE TREATMENT OF CANITIES - At least one compound selected from among coumarin and/or derivative thereof, butylated hydroxyanisole, ethoxyquine and mixtures thereof, and admixtures thereof with other active agents selected from among active agents for combating desquamative conditions of the scalp, plant extracts having propigmenting activity and active agents that slow hair loss and/or promote hair regrowth, are useful for preventing and/or limiting and/or stopping the development of canities. | 2013-06-13 |
20130149361 | ENCAPSULATED PINK TOURMALINE FOR SKIN - Disclosed is a particle, compositions having the particle, and methods of using the particle or composition, that includes a core having an active ingredient, a coating surrounding the core, and pink tourmaline that is included in the core and/or in the coating. | 2013-06-13 |
20130149362 | TREATMENT PRODUCT AND METHOD - Treatment products and methods are disclosed. An example treatment product may be used for treating skin disorders by stimulating the dermis and epidermis skin layers. The example treatment product may have a composition of retinal in the amount of at least 0.15% by weight, and a liposome surrounding the retinal. | 2013-06-13 |
20130149363 | FIVE-LAYERED PIGMENTS - The present invention relates to five-layered pigments based on multicoated platelet-shaped substrates which comprise a layer sequence comprising
| 2013-06-13 |
20130149364 | WATER-BASED PIGMENTED PREPARATION - A water-based pigmented preparation, its production and use and its application in a capillary storage system. | 2013-06-13 |
20130149365 | PERSONAL CARE COMPOSITION COMPRISING AN INORGANIC PIGMENT AND A ORGANIC DYE - The invention relates to personal care compositions for improved skin appearance especially for dark skinned consumers. The personal care composition of the present invention comprises a selective combination of an inorganic pigment particle that has a specific light scattering property (reflection of incident light predominantly in the red region) and an organic dye that has a specific light absorption property (absorption of incident light predominantly in the blue region). This selective combination provides for the highly pleasing even skin appearance. | 2013-06-13 |
20130149366 | PHOTOPROTECTIVE PERSONAL CARE COMPOSITION - The invention relates to photoprotective personal care compositions. It is an object of the present invention to provide for benefits of photoprotection over the visible light region while giving the skin a pleasing even appearance. This is achieved by using a selective combination of an inorganic pigment particle that has a specific light scattering property (reflection of incident light predominantly in the blue region) and an organic dye that has a specific light absorption property (absorption of incident light predominantly in the blue region). | 2013-06-13 |
20130149367 | PROCESSES FOR PRODUCING ANTITOXIC FIBERS AND FABRICS - The invention provides a novel method for producing an antitoxic nonwoven fabric by molecularly grafting the antitoxic molecule thereto. The method comprises immersing a fibrous media comprising a material having a melt flow index of less than 150 MFI in a stable antitoxin solution comprising an antitoxin, preferably triiodide. The wet media is processed through rollers, thereby forcing the antitoxic molecule (e.g., iodine) to penetrate the media. The wet media is dried, and the fabric isolated therefrom. The invention further provides products incorporating the antitoxic media formed by this molecularly grafting method, including a wound dressing, surgical drape, privacy curtain, facemask, gown, article of protective clothing, shoe covering, hair covering, air filter, medical tape, and wipe. | 2013-06-13 |
20130149368 | BIOCELLULOSE DRESSING AND METHOD FOR PREPARING THE SAME - A biocellulose dressing contains a high content of a humectant with superior absorbency and promotes wound healing. The biocellulose dressing contains 10-20% (w/w) of water, 5-30% (w/w) of a microbial cellulose and 50-80% (w/w) of a humectant. A method for preparing dressing is also disclosed. | 2013-06-13 |
20130149369 | COMPOSITION FOR NUCLEIC ACID TRANSFECTION - The invention provides a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates an effective nucleic acid transfection into a cell, and which improves expression of the nucleic acid in the cell. | 2013-06-13 |
20130149370 | HERBAL COMPOSITION FOR PREVENTING AND/OR TREATING ANXIETY RELATED CONDITIONS - The present invention relates to herbal compositions for the treatment and/or prevention of anxiety disorders or stress. These compositions comprise hawthorn fruit (Shan Zha), light wheat grain (Fu xiao mai) and Lilly Bulb (bai hi) in amounts which are effective to treat anxiety conditions. The compositions may further comprise Chinese date (Da zao). | 2013-06-13 |
20130149371 | MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN - A novel family of human mitochondrial RNAs, referred to as chimeric RNAs, which are differentially expressed in normal, pre-cancer and cancer cells, are described. Oligonucleotides targeted to the chimeric RNAs are provided. The described oligonucleotides or their analogs can be used for cancer diagnostics and cancer therapy as well as for research. In one embodiment of this invention, these oligonucleotides hybridize with the sense or with the antisense mitochondrial chimeric RNAs, and the result of the hybridization is useful to differentiate between normal proliferating cells, pre-cancer cells and cancer cells. In another embodiment of the invention, the compositions comprise oligonucleotides that hybridize with the human chimeric RNAs resulting in cancer cell and pre-cancer cell death, while there is no effect in normal cells, constituting therefore, a novel approach for cancer therapy. | 2013-06-13 |
20130149372 | Polypeptides for the Treatment or Prevention of Cancer and uses Thereof - Disclosed herein are polypeptides or their derivatives and their application. The polypeptides and their derivatives can treat or prevent cancer. The polypeptides of the invention have significant lethality to the cancer cells when used alone. When its clinical commonly used chemotherapy drugs such as cisplatin in combination, it can significantly increase the sensitivity of chemotherapeutic agents on cancer cells, to enhance its lethality of cancer cells, to reduce the dosage. The peptides can kill a variety of cancer cells, but without apparent toxicity enhancing effect on normal cells. The prepared peptides of the present invention can be chemically synthesized, high-purity, low molecular weight, specificity, non-immunogenic, safe and reliable. | 2013-06-13 |
20130149373 | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders - Systems, compositions, methods, and kits for identifying potential therapeutic agents for treatment of complement based ocular diseases are provided herein. The methods and kits include a complement component 3 (C3) protein or derivative that is contacted to ocular cells or tissue. Another embodiment of the invention herein provides for diagnosis and/or prognosis of a complement-associated ocular disease. Compositions, methods and kits for regulating or treating a complement-related condition using at least one of CD46 protein, CD55 protein, and a recombinant chimeric soluble terminator of activated complement (STAC) protein or source of the STAC protein. The STAC protein includes an amino acid sequence including at least two of an amino acid sequence of a CD59 protein, an amino acid sequence derived from a CD46 protein, and an amino acid sequence derived from a CD55 protein, optionally further comprising a linker to connect amino acid sequences. | 2013-06-13 |
20130149374 | Asymmetric Liposomes for the Highly Efficient Encapsulation of Nucleic Acids and Hydrophilic Anionic Compounds, and Method for Preparing Same - The present invention relates to asymmetric liposomes for high encapsulation efficiency of nucleic acids and hydrophilic anionic compounds, and to a method for preparing same, and specifically, to asymmetric liposomes consisting of a cationic lipid having a small head group as an internal lipid and a neutral or PEGylated lipid having a big head group as an external lipid, wherein nucleic acids and/or anionic compounds are encapsulated in the internal lipid. According to the present invention, asymmetric liposomes, in which nucleic acids and hydrophilic anionic compounds are encapsulated with high efficiency, may be prepared, and thus the same may be used for various purposes, such as gene therapy, and the delivery of hydrophilic anionic drugs which are difficult to prepare as prodrugs, and drug delivery, imaging, etc. can be carried out by encapsulating a fluorescent contrast agent in the liposome. | 2013-06-13 |
20130149375 | IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA - RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal | 2013-06-13 |
20130149376 | VACCINE COMPOSITION BASED ON STICHOLYSIN ENCAPSULATED INTO LIPOSOMES - The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into multilamellar vesicles obtained by the dehydration-rehydration procedure whose lipidic composition is dipalmitoylphosphatidylcholine:cholesterol in a 1:1 molar ratio for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. | 2013-06-13 |
20130149377 | CUSTOM-PILL COMPOUNDING SYSTEM WITH FILLER-FREE CAPABILITY - A system and associated aspects thereof are disclosed regarding custom-compounding of drug products such as pills and polypills for particular patients, herein involving adaptations of “micro-dosing” technology to permit sufficiently small and precise amounts of drug substances or optionally formulations thereof to be controllably and automatably handled and dispensed so as to help create customized drug products that do not necessitate bulking or dilution of the drug substances. | 2013-06-13 |
20130149378 | Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof - An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The compound includes 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100-900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10-500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β-tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol-free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides. | 2013-06-13 |
20130149379 | GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT - Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate. | 2013-06-13 |
20130149380 | USE OF DIATOMACEOUS EARTH IN THE PHARMACEUTICAL INDUSTRY - The present invention is related to solid pharmaceutical preparations containing diatomaceous earth (diatomite) or a natural mineral mixture containing diatomaceous earth as filler besides the active ingredient and optional other auxiliary agents. A further object of the invention is a method for manufacturing such pharmaceutical preparations. | 2013-06-13 |
20130149381 | ABSORPTION METHOD FOR ENTRAPMENT OF DRUGS IN POLYMERIC NANOPARTICLES - A method for preparing polymeric nanoparticles having entrapped active ingredients or drugs, the method includes the step of preparing a reaction by mixturing water, a surfactant, and a water-soluble radical initiator; polymerizing a polymerizable monomer in the reaction to obtain a dispersion of polymeric nanoparticles having a controlled size with average diameters smaller than 50 nm; dissolving one or more active ingredients in a suitable solvent; adding the solution of active ingredients to the dispersion of polymeric nanoparticles and allowing that the active ingredients to become entrapped within polymeric nanoparticles; and evaporating the dispersion of polymeric nanoparticles having entrapped active ingredients to evaporate the residual monomer and the solvent used as a vehicle for loading the active ingredient. | 2013-06-13 |
20130149382 | LIQUID COMPOSITIONS COMPRISING A SUSTAINED RELEASE SYSTEM FOR INSECTICIDES - Liquid formulations for controlling arthropod infestation that comprise particles carrying chemical agents that have activity against arthropods, the particles being suspended within the liquid formulation, uses therefor, and methods of producing such liquid formulations. | 2013-06-13 |
20130149383 | SUSTAINED RELEASE PARTICLE FORMULATIONS OF GUAIFENESIN - Sustained release particle formulations formed from a hydrophobic wax matrix and guaifenesin. | 2013-06-13 |
20130149384 | THERMAL INACTIVATION OF ROTAVIRUS - Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus. | 2013-06-13 |
20130149385 | NANOFORMULATION OF VITAMIN D DERIVATIVES AND/OR VITAMIN D METABOLITES - A nanoformulation that includes loaded nanoparticles. Each nanoparticle includes a modified chitosan polymer encapsulating at least one vitamin D derivative, at least one vitamin D metabolite, or combinations thereof. The modified chitosan polymer includes chitosan covalently linked to at least one entity selected from the group consisting of fatty acids (omega-3-fattay acids), amino acids, deoxycholic acid, alginate, arginine-alginate, hyaluronic acid, collagen, collagen-hydroxyapatite, poly(lactic-co-glycolic acid) (PLGA), and combinations thereof. A structure includes a medium and the nanoformulation, wherein the nanoparticles are dispersed in the medium. A method of using the nanoformulation to treat a disorder and improve efficacy of current therapies where resistance develop in a patient includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the disorder. A nano-cosmetic formulation, comprising a cosmetic includes the nanoformulation, wherein the modified chitosan polymer encapsulates the at least one vitamin D derivative, and wherein the at least one vitamin D derivative encompasses 0.1 to 20.0 wt % of the nano-cosmetic formulation's total weight. | 2013-06-13 |
20130149386 | CD36 AS BIOMARKER FOR STEATOSIS - A method is provided for early treatment of steatosis, which method is based on early detection of steatosis based on the detection of CD36. CD36 is determined in a body fluid, and CD36 levels above a predetermined value is indicative of steatosis. | 2013-06-13 |
20130149387 | BIODEGRADABLE TISSUE COMPOSITION WITH BIODEGRADABLE CROSS-LINKERS - Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue are also described. Methods and compositions to obtain a degradable implantable tissue-synthetic biodegradable polymer composite are also described. Compositions and methods of incorporating substantially water-insoluble bioactive compounds in the implantable tissue are also disclosed. The use of membrane-like implantable tissue to make an implantable drug delivery patch are also disclosed. Also described are the compositions and methods to obtain a coated implantable tissue. Medical applications implantable tissue such as heart valve bioprosthesis, vascular grafts, meniscus implant, drug delivery patch are also disclosed. | 2013-06-13 |
20130149388 | METABOLOMICS-BASED BIOMARKERS FOR LUNG FUNCTION - Chronic obstructive pulmonary disease (COPD), characterized by chronic airflow limitation, is a serious and growing public health concern. The major environmental risk factor for COPD is cigarette smoking, but the biological mechanisms underlying COPD are not well understood. Herein, proton nuclear magnetic resonance ( | 2013-06-13 |
20130149389 | BIOMARKERS OF LUNG FUNCTION - Cigarette smoking is a primary determinant of chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of morbidity and mortality in the United States. Unique proteins associated with COPD capable of differentiating subjects likely to experience rapid (RPD) or slow (SLW) decline in lung function have been identified using comprehensive high-throughput proteomic approaches. Thirty peptides, which mapped to 21 unique proteins, were linearly associated with annualized rates of lung function decline among smokers with COPD characterized as having rapid or slow decline and smokers without COPD. Using three different statistical approaches to assess the data, the RPD and SLW groups are differentiated by 55 peptides, which mapped to 33 unique proteins. A number of the identified peptides are proteolytic fragments of proteins that are involved in the complement and/or coagulation systems, have anti-protease activity, or metabolic functions. | 2013-06-13 |
20130149390 | Method for Bowel Preparation - The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty. | 2013-06-13 |
20130149391 | FLUORIDE VARNISH COMPOSITIONS INCLUDING AN ORGANO PHOSPHORIC ACID ADHESION PROMOTING AGENT - Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors. | 2013-06-13 |
20130149392 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER WITH BIS-(THIOHYDRAZIDE)AMIDE COMPOUNDS - The present invention is a method for treating non-small cell lung cancer in a subject in need thereof, comprising administering to the subject an effective amount of a bis(thiohydrazideamide) compound of formula (I): | 2013-06-13 |
20130149393 | MEDICAL COMPOSITIONS CONTAINING LIQUORICE EXTRACTS WITH SYNERGISTIC EFFECT - The invention provides drug compositions with synergistic effects, which includes alcohol-soluble and water-insoluble liquorices extracts and at least one kind of anti-tumor or glucose-and-lipid-lowering drug/eatable substance, and can be used to treat tumor or lower blood glucose and lipid. Besides, the invention also provides pharmaceutical preparation, pharmaceutical application, therapeutic and preparation methods, etc. related to this drug compositon. | 2013-06-13 |
20130149394 | AQUEOUS OPHTHALMIC COMPOSITION - The invention provides an aqueous ophthalmic composition, containing a beta blocker such as timolol, carteolol or the like, and a sugar alcohol such as mannitol, sorbitol or the like, optionally together with boric acid. The composition of the invention can improve the corneal permeability of a drug, so that the dose of the drug can be lowered, for example by decreasing the frequency of application to the eyes. It is therefore expected that the risk of systemic side effects which may be induced by the application of the beta blocker to the eyes, including cardiotoxicity or respiratory toxicity can be reduced. The decrease in the frequency of application of ophthalmic solution can favorably improve the QOL and prevent the decrease of therapeutic effect which may be caused by missing the application to the eyes. | 2013-06-13 |
20130149395 | Pharmaceutical Product, Method of Production and Method of Application of the Pharmaceutical Product - The claimed pharmaceutical product is obtained by interaction between a selenium-containing compound with alpha, alpha-dichlorocarboxylic acid, stabilized by nutric acid with the amount of nitric acid not exceeding 5 pts. wt., preferably 1-3 pts. As a selenium-containing compound the solution of the selenious acid in the amount of no more than 20 pts. wt., preferably 0.5-10.0 pts. wt. is used during the interaction. The product can also contain additional 5-20% of dimethylsulfoxide. The production process of the pharmaceutical product is carried out by interaction between a selenium-containing compound with alpha, alpha-dichlorocarboxylic acid, stabilized by nutric acid with the amount of nitric acid not exceeding 5 pts. wt., preferably 1-3 pts., and as a selenium-containing compound the solution of the selenious acid in the amount of no more than 20 pts. wt., preferably 0.5-10.0 pts. wt. is used during the interaction, which is carried out at the temperature not exceeding 70° C., preferably at 20-30° C. The pharmaceutical product used for the treatment of benign, viral, pre-malignant and malignant non-metastatic skin lesions, dysplastic lesions of visible mucous coats and other skin lesions, should be applied to the lesion focus on days 1, 2-3, 7-9 and 22-24 of a treatment. | 2013-06-13 |
20130149396 | Silicate Containing Compositions and Methods of Treatment - The present invention relates to compositions comprising a silicate and methods of use thereof. In particular, the compositions of the present invention are suitable for treating inflammatory conditions, cancer, bacterial and viral infections, and infected and uninfected wounds. The compositions of the present invention can also be useful in treating spinal cord injury, tissue remodeling, and promoting bone growth and repair. | 2013-06-13 |
20130149397 | Modulation of Thymosin Beta-4 in Skin - Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents, other than a retinoid, that stimulate thymosin beta-4 expression in the skin. Also provided are methods for screening for substances which stimulate thymosin beta-4 expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin. | 2013-06-13 |
20130149398 | COMPOSITIONS OF HERBAL FORMULATIONS AND USES THEREOF - Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient. | 2013-06-13 |
20130149399 | SKIN TEMPERATURE ELEVATING AGENT, AND COSMETIC COMPOSITION, FOOD AND SUNDRY ARTICLE CONTAINING THE SAME - An object of the present invention is to provide a skin temperature elevating agent that can further effectively raise a skin temperature. Another object is to provide a cosmetic composition, a food and a sundry article having a skin temperature elevating effect. A skin temperature elevating agent of the present invention is selected from one or more selected from a group consisting of: an extract of Japanese peppermint; an extract of clary sage; dihydro-β-ionol; and geraniol, and thus it can raise a skin temperature of a cheek. The skin temperature elevating agent according to the present invention is also selected from one or more selected from a group consisting of: an extract of Japanese peppermint; an extract of juniper berry; and 4-methoxystyrene, and thus it can raise a skin temperature of a hand fingertip. Hence, the skin temperature elevating agent according to the present invention can further effectively raise a skin temperature. A composition, a food, and a sundry article according to the present invention contain the skin temperature elevating agent, and thus have the skin temperature elevating effect. | 2013-06-13 |
20130149400 | Cobweb Inhibitor and Spider Repellent - A composition which is fatal and repellant to pests such as spiders, insect, and mold is disclosed. In concentrate form, the composition includes from about 1 to about 50 percent, by weight, of at least one surfactant; from about 1 to about 50 percent, by weight, of at least one essential oil; optionally, from about 2 to about 50 percent, by weight, of at least one carboxylic acid having from 1 to 6 carbon atoms and optionally from about 5 to about 50 percent, by weight, of at least one alcohol having from 1 to 6 carbon atoms, wherein all percentages are based on the concentrate in undiluted form. The concentrate may also be diluted with a solvent prior to use. | 2013-06-13 |
20130149401 | COMPOSITIONS COMPRISING KAKADU PLUM EXTRACT OR ACAI BERRY EXTRACT - A topical skin care composition comprising kakadu plum extract or acai berry extract, or a combination of both, is disclosed. The composition can include a high oxygen radical absorbance capacity (ORAC) value. The composition can improve the skin's visual appearance, physiological functions, clinical properties, and/or biophysical properties. | 2013-06-13 |
20130149402 | Press System for Forming a Composite Article - A press with a pressure chamber and a lid. The chamber is filled with a substantially incompressible medium and the medium at least partially encloses an elastomeric pressure vessel. The vessel is filled with a substantially incompressible fluid that is in fluid communication with a pressurized source of the fluid. | 2013-06-13 |
20130149403 | Die, System, and Method for Coextruding A Plurality Of Fluid Layers - A die for coextruding a plurality of fluid layers generally includes a primary forming stem, one or more distribution plates, and a microlayer assembly. The microlayer assembly includes a microlayer forming stem and a plurality of microlayer distribution plates. | 2013-06-13 |
20130149404 | LENS MANUFACTURING APPARATUS - A lens manufacturing apparatus includes a concave-convex shape forming unit that makes a notch in the surface of a workpiece to form a concave-convex shape portion, a resin supply unit that supplies resin for a lens onto the surface of the workpiece, a resin curing unit that cures the supplied resin for a lens, a moving unit that moves the concave-convex shape forming unit, the resin supply unit, and the resin curing unit relative to the workpiece, and a control unit that controls driving of the concave-convex shape forming unit, the resin supply unit, the resin curing unit, and the moving unit so as to form the concave-convex shape portion extending in a predetermined direction, supply the resin for a lens between adjacent concave-convex shape portions and cure the supplied resin for a lens. | 2013-06-13 |
20130149405 | DEVICE FOR MANUFACTURING OPTICAL FILM - Provided is a device for manufacturing an optical film having satisfactorily reduced thickness unevenness, by using a melt-casting film forming method, which device includes a casting die for discharging a molten film-forming material including a thermoplastic resin into a film-like shape; a pair of a first rotation roll and a second rotation roll between which the discharged film-shaped molten article is pinched to be cooled and solidified to make the film shaped molten article; and two pairs of wind shield plates each of which pairs are arranged between the shaft-direction ends of the first and second rotation rolls and an end part in the width-direction of the film-shaped molten article, wherein the wind shield plates are placed approximately perpendicular to the surface of the film-shaped molten article, and wherein each pair of the wind shield plates are placed approximately in parallel. | 2013-06-13 |
20130149406 | EXTRUSION DIE HEAD - When extrusion molding is conducted continuously for a long period of time, in order to prevent a die drool from being generated at an outlet of an extruder, to a shell | 2013-06-13 |
20130149407 | MOLD FOR FABRICATING LIGHT GUIDING PLATE - A mold for fabricating a light guiding plate includes an upper mold, a lower mold and a die core assembly. The upper mold defines a first cooling channel therein. The lower mold defines a cavity thereon. The die core assembly is mounted on the upper mold, and includes a base plate connected to the upper mold and a core plate detachably located at a side of the base plate facing the lower mold. The base plate defines a second cooling channel. The second cooling channel communicates with the first cooling channel respectively to cooling the mold. | 2013-06-13 |
20130149408 | BLOW MOLDING APPARATUS - In an embodiment, a neck mold assembly includes N rows of holding plates, each of the N rows of holding plates holding a plurality of neck molds. The neck mold assembly also includes a supporting-mechanism that supports the N rows of holding plates. The supporting mechanism includes at least one reinforcement shaft that is provided along a row direction of the N rows of holding plates, and two first securing sections that are secured at either end of the at least one reinforcement shaft. Each of the N rows of holding plates has at least one first through-hole that receives the at least one reinforcement shaft. | 2013-06-13 |
20130149409 | INJECTION MOLD - An injection mold including a first mold, a second mold disposed opposite to the first mold and configured to form a cavity having a shape that corresponds to an injection-molded product to be manufactured by being coupled to the first mold, an injection apparatus configured to inject molten resin in the cavity, and an adsorption apparatus configured to adsorb and separate the injection-molded product, which is manufactured by the first mold and the second mold, from the first mold, so that the separation of the injection-molded product is performed by the adsorption apparatus, and thus structures configured to separate the injection-molded product are omitted from the first mold and the second mold, thereby simplifying the structures of the first mold and the second mold. | 2013-06-13 |
20130149410 | APPARATUS FOR MOLDING CRASH PAD FOR VEHICLE - Provided is an apparatus for molding a crash pad for a vehicle, which includes a first metal mold in which an insert cavity is formed, a second metal mold installed opposite the first metal mold, an insert inserted into the insert cavity and having a through-hole toward the first metal mold so as to define a boundary between an upper part and a lower part of the crash pad that is injection-molded by the first and second metal molds, and a resin introducing unit installed in the first metal mold abutting on the insert and having an elastically adjusted space into which molding resin is introduced through the through-hole when an injection pressure exceeds a predetermined level. | 2013-06-13 |
20130149411 | PROCESS AND METHOD FOR OPTIMIZING PRODUCTION OF FOOD AND FEED - A process includes microbially degrading harvested polyculture plant material to form a concentrated microbial biomass and providing the concentrated microbial biomass to an intermediary animal for consumption. The process may also be directed to producing a product animal which includes providing a growth area having an outlet for waste and providing a harvested plant material collection area having an outlet for degradation products. The process may also include providing a microbial growth system for producing a bacterial biomass and directing at least some waste from the outlet of the product animal growth area to the harvested plant material collection area. The process may also include directing at least some degradation products to the microbial growth system, directing some of the microbial biomass produced in the microbial growth system to an intermediary animal for consumption, and directing the intermediary animal to a product animal growth area. | 2013-06-13 |
20130149412 | AMORPHOUS CHEWING GUM BULK MATERIAL - A bulk material suitable for use in a chewing gum contains at least about 40 wt. % dry basis sorbitol, at least about 7 wt. % dry basis other than sorbitol, and no more than about 10 wt. % water, wherein the bulk material is amorphous and remains amorphous with shear. A chewing gum, comprising: a) a gum base; b) a flavor; and c) a bulk material contains at least 40 wt. % dry basis sorbitol, at least 7 wt. % dry basis polyol other than sorbitol and no more than 10 wt. % water. | 2013-06-13 |
20130149413 | OAT-DERIVED SWEETENER - A process for forming a syrup product that is suitable for use in a food product. A base formulation is prepared having a major amount of an oat material or waxy barley hybrid. The base formulation is mixed with water to form a slurry. At least one enzyme is mixed into the slurry. The slurry is cooked to convert the slurry into an intermediate product. The intermediate product is evaporated to produce a syrup product having a solids level of at least 65 Brix. | 2013-06-13 |
20130149414 | PROCESSING OF VEGETABLE OILS - A process for interesterifying a vegetable oil comprises treating the vegetable oil by contacting the vegetable oil with a natural adsorbent to give a pH in the range of from 6 to 8, separating the oil from the adsorbent and reacting the treated oil in the presence of an enzymatic catalyst for interesterification. | 2013-06-13 |
20130149415 | Use of manganese for enhancing the growth of L.casei in mixed cultures. - The invention relates to a method for selectively enhancing the growth of bacteria from the | 2013-06-13 |
20130149416 | TEA BAG AND METHOD FOR MANUFACTURING THE SAME - There are provided a tea bag that can be easily taken out of a plastic bottle and excels in mass productivity, and a method for manufacturing the same. As for tea bag | 2013-06-13 |
20130149417 | CONTAINER SYSTEM - A container system is described. In one or more implementations, the container system comprises a lower container for receiving a first food component (or components) and an upper container assembly for receiving a second food component (or components) so that the second food component is separated from the first food component. The upper container assembly is configured for engagement with the lower container and is operable to be at least partially opened while the upper container assembly is engaged with the lower container to introduce the second food component into the lower container with the first food component. In one or more embodiments, a pull tab is coupled to the upper container assembly. The pull tab is configured to be pulled while the upper container assembly is engaged with the lower container to at least partially open the upper container assembly. | 2013-06-13 |